Metabolism, Inborn Errors
15 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Broader: Metabolic Diseases
Narrower: Adrenal Hyperplasia, Congenital 1, Glycogen Storage Disease Type I 1, Hemochromatosis 1, Homozygous Familial Hypercholesterolemia 2, Hyperlipoproteinemia Type I 1, Hyperlipoproteinemia Type II 4, Hyperlipoproteinemia Type V 1, Hypophosphatasia 1, Lysosomal Storage Diseases 1, Propionic Acidemia 1
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| BBI-001 for hemochromatosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BEAM-301: Single dose of BEAM-301 administered by IV for glycogen storage disease type i | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CTX310 for homozygous familial hypercholesterolemia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CTX310 for hyperlipoproteinemia type v | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Efzimfotase Alfa for hypophosphatasia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Enlicitide Decanoate for hyperlipoproteinemia type ii | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| mRNA-3927 for propionic acidemia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Olezarsen for hyperlipoproteinemia type i | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Osilodrostat for adrenal hyperplasia, congenital | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for metabolism, inborn errors | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phase 2 Established Dose from prior study, NCT03810196 for metabolism, inborn errors | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phase 2 Maximum Tolerated Dose determined in Phase 1 for metabolism, inborn errors | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RP-A501 for lysosomal storage diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SHR-1918 for homozygous familial hypercholesterolemia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VERVE-102 for hyperlipoproteinemia type ii | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.